Loading
NASDAQHealthcareBiotechnology
Latest quote
$71.21
+$0.87 · +1.24%
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Regular session
$71.21
+$0.87 · +1.24%
Regular session · ET · Market data may be delayed.
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Day range
Current $71.21
52-week range
Current $71.21
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
36
Expensive
Sentiment
45
Mixed
Risk
54
Elevated Risk
Momentum
77
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Day range
Current $71.21
52-week range
Current $71.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 19.39M USD | 11.54M USD | 1.55M USD | 3.88M USD | 31.27M USD |
| Cost of goods sold | — | — | — | 12.68M USD | 20.38M USD |
| Gross profit | 19.39M USD | 11.54M USD | 1.55M USD | −8.8M USD | 10.89M USD |
| Research and development | 22.8M USD | 17.8M USD | 23.54M USD | 12.68M USD | 20.38M USD |
| Selling, general, and administrative | 4.18M USD | 5.75M USD | 7.37M USD | 7.45M USD | 8.45M USD |
| Operating expenses | 26.93M USD | 23.55M USD | 30.86M USD | 7.45M USD | 7.93M USD |
| Interest income | 1.41M USD | 1.43M USD | 2.07M USD | 1.32M USD | 257K USD |
| Depreciation and amortization | 109K USD | 233K USD | 342K USD | 562K USD | 880K USD |
| Operating income | −7.54M USD | −12.01M USD | −29.31M USD | −16.24M USD | 2.96M USD |
| Net income | −6.13M USD | −10.58M USD | −27.24M USD | −14.92M USD | 3.22M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$110
54.47% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
